Appelman, M.D.* et al. NTCP ubiquitination enables HBV infection. JHEP Rep. 7:101534 (2025)
Hoegen-Saßmannshausen, P.* et al. Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial. JHEP Rep. 6:101063 (2024)
Ringelhan, M.* et al. HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx. JHEP Rep. 6:101128 (2024)
Su, J. et al. Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component. JHEP Rep. 6:100997 (2024)
Clerbaux, L.A.* et al. Mcl-1 deficiency in murine livers leads to nuclear polyploidisation and mitotic errors: Implications for hepatocellular carcinoma. JHEP Rep. 5:100838 (2023)
Sacherl, J. et al. Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance. JHEP Rep. 5:100603 (2023)
Tu, T.* et al. Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells. JHEP Rep. 4:100514 (2022)
Faure-Dupuy, S.* et al. Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p. JHEP Rep. 3:100354 (2021)